Bangalore: Biocon Ltd has displayed the outcomes of phase-I studies on its oral insulin product, IN-105, at the European Association for Study of Diabetes conference held in Amsterdam on Friday.

In a statement, the company said that phase-I studies were carried out on strong volunteers who have been given IN-105 in the pill form. Derived from these hopeful consequences, Biocon destines to now build up this molecule through with more clinical examinations.

IN-105 is Biocon’s new proprietary insulin analog, and is feasible for delivery as tab at room temperature.

Biocon’s CMD, Kiran Mazumdar-Shaw, told, “This is an encouraging step towards our efforts of bringing oral insulin to diabetic patients across the world. IN-105 promises to be a significant value differentiator in Biocon’s quest for global leadership in the insulin segment.”

Biocon has carried on all the growth for this molecule at its Bangalore facilities.

Recently, it has got nod from the Swedish medical authorities to perform phase-I human clamp studies for the molecule in Sweden- the first clinical trial outside India for the molecule.